Cargando…
A cost-effectiveness analysis of an in-hospital clinical pharmacist service
OBJECTIVE: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic mo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253415/ https://www.ncbi.nlm.nih.gov/pubmed/22223840 http://dx.doi.org/10.1136/bmjopen-2011-000329 |
_version_ | 1782220728082366464 |
---|---|
author | Wallerstedt, Susanna M Bladh, Lina Ramsberg, Joakim |
author_facet | Wallerstedt, Susanna M Bladh, Lina Ramsberg, Joakim |
author_sort | Wallerstedt, Susanna M |
collection | PubMed |
description | OBJECTIVE: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic model. DESIGN: A piggyback cost-effectiveness analysis from the healthcare perspective. SETTING: Two internal medicine wards at Sahlgrenska University Hospital, Göteborg, Sweden. PARTICIPANTS: Of 345 patients (61% women; median age: 82 years; 181 control and 164 intervention patients), 240 patients (62% women, 82 years; 124 control and 116 intervention patients) had EuroQol-5 dimensions (EQ-5D) utility scores at baseline and at 6-month follow-up. OUTCOME MEASURES: Costs during a 6-month follow-up period in all patients and incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) in patients with EQ-5D utility scores. Inpatient and outpatient care was extracted from the VEGA database. Drug costs were extracted from the Swedish Prescribed Drug Register. A probabilistic analysis was performed to characterise uncertainty in the cost-effectiveness model. RESULTS: No significant difference in costs between the randomisation groups was found; the mean total costs per individual±SD, intervention costs included, were €10 748±13 799 (intervention patients) and €10 344±14 728 (control patients) (p=0.79). For patients in the cost-effectiveness analysis, the corresponding costs were €10 912±13 999 and €9290±12 885. Intervention patients gained an additional 0.0051 QALYs (unadjusted) and 0.0035 QALYs (adjusted for baseline EQ-5D utility score). These figures result in an incremental cost-effectiveness ratio of €316 243 per unadjusted QALY and €463 371 per adjusted QALY. The probabilistic uncertainty analysis revealed that, at a willingness-to-pay of €50 000/QALY, the probability that the intervention was cost-effective was approximately 0.2. CONCLUSIONS: The present study reveals that an intervention designed like this one is probably not cost-effective. The study thus illustrates that the complexity of healthcare requires thorough health economics evaluations rather than simplistic interpretation of data. |
format | Online Article Text |
id | pubmed-3253415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32534152012-01-17 A cost-effectiveness analysis of an in-hospital clinical pharmacist service Wallerstedt, Susanna M Bladh, Lina Ramsberg, Joakim BMJ Open Pharmacology and Therapeutics OBJECTIVE: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic model. DESIGN: A piggyback cost-effectiveness analysis from the healthcare perspective. SETTING: Two internal medicine wards at Sahlgrenska University Hospital, Göteborg, Sweden. PARTICIPANTS: Of 345 patients (61% women; median age: 82 years; 181 control and 164 intervention patients), 240 patients (62% women, 82 years; 124 control and 116 intervention patients) had EuroQol-5 dimensions (EQ-5D) utility scores at baseline and at 6-month follow-up. OUTCOME MEASURES: Costs during a 6-month follow-up period in all patients and incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) in patients with EQ-5D utility scores. Inpatient and outpatient care was extracted from the VEGA database. Drug costs were extracted from the Swedish Prescribed Drug Register. A probabilistic analysis was performed to characterise uncertainty in the cost-effectiveness model. RESULTS: No significant difference in costs between the randomisation groups was found; the mean total costs per individual±SD, intervention costs included, were €10 748±13 799 (intervention patients) and €10 344±14 728 (control patients) (p=0.79). For patients in the cost-effectiveness analysis, the corresponding costs were €10 912±13 999 and €9290±12 885. Intervention patients gained an additional 0.0051 QALYs (unadjusted) and 0.0035 QALYs (adjusted for baseline EQ-5D utility score). These figures result in an incremental cost-effectiveness ratio of €316 243 per unadjusted QALY and €463 371 per adjusted QALY. The probabilistic uncertainty analysis revealed that, at a willingness-to-pay of €50 000/QALY, the probability that the intervention was cost-effective was approximately 0.2. CONCLUSIONS: The present study reveals that an intervention designed like this one is probably not cost-effective. The study thus illustrates that the complexity of healthcare requires thorough health economics evaluations rather than simplistic interpretation of data. BMJ Group 2012-01-05 /pmc/articles/PMC3253415/ /pubmed/22223840 http://dx.doi.org/10.1136/bmjopen-2011-000329 Text en © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Pharmacology and Therapeutics Wallerstedt, Susanna M Bladh, Lina Ramsberg, Joakim A cost-effectiveness analysis of an in-hospital clinical pharmacist service |
title | A cost-effectiveness analysis of an in-hospital clinical pharmacist service |
title_full | A cost-effectiveness analysis of an in-hospital clinical pharmacist service |
title_fullStr | A cost-effectiveness analysis of an in-hospital clinical pharmacist service |
title_full_unstemmed | A cost-effectiveness analysis of an in-hospital clinical pharmacist service |
title_short | A cost-effectiveness analysis of an in-hospital clinical pharmacist service |
title_sort | cost-effectiveness analysis of an in-hospital clinical pharmacist service |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253415/ https://www.ncbi.nlm.nih.gov/pubmed/22223840 http://dx.doi.org/10.1136/bmjopen-2011-000329 |
work_keys_str_mv | AT wallerstedtsusannam acosteffectivenessanalysisofaninhospitalclinicalpharmacistservice AT bladhlina acosteffectivenessanalysisofaninhospitalclinicalpharmacistservice AT ramsbergjoakim acosteffectivenessanalysisofaninhospitalclinicalpharmacistservice AT wallerstedtsusannam costeffectivenessanalysisofaninhospitalclinicalpharmacistservice AT bladhlina costeffectivenessanalysisofaninhospitalclinicalpharmacistservice AT ramsbergjoakim costeffectivenessanalysisofaninhospitalclinicalpharmacistservice |